128 related articles for article (PubMed ID: 38245408)
1. Surgeon seniority and experience have no effect on CaP detection rates using MRI/TRUS fusion-guided targeted biopsies.
Taha F; Larre S; Branchu B;
Urol Oncol; 2024 Mar; 42(3):67.e1-67.e7. PubMed ID: 38245408
[TBL] [Abstract][Full Text] [Related]
2. Systematic prostate biopsy still matters: A comprehensive analysis of MRI/TRUS-fusion targeted prostate biopsies across different indications.
Westhoff N; Baeßler B; von Hardenberg J; Hetjens S; Porubsky S; Siegel F; Martini T; Michel MS; Attenberger U; Ritter M
Urol Oncol; 2019 Oct; 37(10):678-687. PubMed ID: 31375340
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies.
Filson CP; Natarajan S; Margolis DJ; Huang J; Lieu P; Dorey FJ; Reiter RE; Marks LS
Cancer; 2016 Mar; 122(6):884-92. PubMed ID: 26749141
[TBL] [Abstract][Full Text] [Related]
4. The use of 29 MHz transrectal micro-ultrasound to stratify the prostate cancer risk in patients with PI-RADS III lesions at multiparametric MRI: A single institutional analysis.
Avolio PP; Lughezzani G; Paciotti M; Maffei D; Uleri A; Frego N; Hurle R; Lazzeri M; Saita A; Guazzoni G; Casale P; Buffi NM
Urol Oncol; 2021 Dec; 39(12):832.e1-832.e7. PubMed ID: 34183255
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of prostate cancer identified by transperineal standard template biopsy in men with nonsuspicious multiparametric magnetic resonance imaging.
Dahl DM; Wu S; Lin SX; Hu M; Barney AA; Kim MM; Cornejo KM; Harisinghani MG; Feldman AS; Wu CL
Urol Oncol; 2024 Feb; 42(2):28.e21-28.e28. PubMed ID: 38182499
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of systematic, targeted and combined prostate biopsies for the diagnosis of prostate cancer with MRI lesion].
Gander J; Guandalino M; Vedrine N; Charbonnel C; Gayrel P; Ceruti F; Guy L
Prog Urol; 2022 Oct; 32(12):836-842. PubMed ID: 35577670
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer detection using magnetic resonance imaging-transrectal ultrasound fusion biopsy: A retrospective cohort study.
Pratihar SK; Khanna A; Vasudeo V; Gupta R; Saurabh N; Kumar B; Ali M; Akotkar SS; Rawal SK; Singh A
Indian J Urol; 2023; 39(4):297-302. PubMed ID: 38077193
[TBL] [Abstract][Full Text] [Related]
8. Defining the learning curve for multiparametric magnetic resonance imaging (MRI) of the prostate using MRI-transrectal ultrasonography (TRUS) fusion-guided transperineal prostate biopsies as a validation tool.
Gaziev G; Wadhwa K; Barrett T; Koo BC; Gallagher FA; Serrao E; Frey J; Seidenader J; Carmona L; Warren A; Gnanapragasam V; Doble A; Kastner C
BJU Int; 2016 Jan; 117(1):80-6. PubMed ID: 25099182
[TBL] [Abstract][Full Text] [Related]
9. Reducing the demand for magnetic resonance imaging scans and prostate biopsies during the early detection of clinically significant prostate cancer: Applying the Barcelona risk-stratified pathway in Catalonia.
Morote J; Borque-Fernando Á; Esteban LE; Picola N; Muñoz-Rodriguez J; Paesano N; Ruiz-Plazas X; Muñoz-Rivero MV; Celma A; García-de Manuel G; Miró B; Abascal JM; Servian P
Urol Oncol; 2024 Apr; 42(4):115.e1-115.e7. PubMed ID: 38342654
[TBL] [Abstract][Full Text] [Related]
10. Changes in prostate cancer detection rate of MRI-TRUS fusion vs systematic biopsy over time: evidence of a learning curve.
Calio B; Sidana A; Sugano D; Gaur S; Jain A; Maruf M; Xu S; Yan P; Kruecker J; Merino M; Choyke P; Turkbey B; Wood B; Pinto P
Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):436-441. PubMed ID: 28762373
[TBL] [Abstract][Full Text] [Related]
11. Limitations of overlapping cores in systematic and MRI-US fusion biopsy.
Lee AY; Yang XY; Lee HJ; Law YM; Huang HH; Sim AS; Lau WK; Lee LS; Cheng CW; Ho HS; Yuen JS; Tay KJ; Chen K
Urol Oncol; 2021 Nov; 39(11):782.e15-782.e21. PubMed ID: 33888423
[TBL] [Abstract][Full Text] [Related]
12. An initial negative round of targeted biopsies in men with highly suspicious multiparametric magnetic resonance findings does not exclude clinically significant prostate cancer-Preliminary experience.
Costa DN; Kay FU; Pedrosa I; Kolski L; Lotan Y; Roehrborn CG; Hornberger B; Xi Y; Francis F; Rofsky NM
Urol Oncol; 2017 Apr; 35(4):149.e15-149.e21. PubMed ID: 27939349
[TBL] [Abstract][Full Text] [Related]
13. Transperineal Versus Transrectal MRI/TRUS Fusion Targeted Biopsy: Detection Rate of Clinically Significant Prostate Cancer.
Pepe P; Garufi A; Priolo G; Pennisi M
Clin Genitourin Cancer; 2017 Feb; 15(1):e33-e36. PubMed ID: 27530436
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of MR/ultrasound fusion-guided biopsy in patients with lower suspicion lesions on active surveillance for low-risk prostate cancer.
Lokeshwar SD; Nguyen J; Rahman SN; Khajir G; Ho R; Ghabili K; Leapman MS; Weinreb JC; Sprenkle PC
Urol Oncol; 2022 Sep; 40(9):407.e21-407.e27. PubMed ID: 35811206
[TBL] [Abstract][Full Text] [Related]
15. In patients with a previous negative prostate biopsy and a suspicious lesion on magnetic resonance imaging, is a 12-core biopsy still necessary in addition to a targeted biopsy?
Salami SS; Ben-Levi E; Yaskiv O; Ryniker L; Turkbey B; Kavoussi LR; Villani R; Rastinehad AR
BJU Int; 2015 Apr; 115(4):562-70. PubMed ID: 25252133
[TBL] [Abstract][Full Text] [Related]
16. Fusion prostate biopsy outperforms 12-core systematic prostate biopsy in patients with prior negative systematic biopsy: A multi-institutional analysis.
Sidana A; Watson MJ; George AK; Rastinehad AR; Vourganti S; Rais-Bahrami S; Muthigi A; Maruf M; Gordetsky JB; Nix JW; Merino MJ; Turkbey B; Choyke PL; Wood BJ; Pinto PA
Urol Oncol; 2018 Jul; 36(7):341.e1-341.e7. PubMed ID: 29753548
[TBL] [Abstract][Full Text] [Related]
17. The utility of in-bore multiparametric magnetic resonance-guided biopsy in men with negative multiparametric magnetic resonance-ultrasound software-based fusion targeted biopsy.
Perrin A; Venderink W; Patak MA; Möckel C; Fehr JL; Jichlinski P; Porcellini B; Lucca I; Futterer J; Valerio M
Urol Oncol; 2021 May; 39(5):297.e9-297.e16. PubMed ID: 33341358
[TBL] [Abstract][Full Text] [Related]
18. Cancer detection rate of prebiopsy MRI with subsequent systematic and targeted biopsy are superior to non-targeting systematic biopsy without MRI in biopsy naïve patients: a retrospective cohort study.
Washino S; Kobayashi S; Okochi T; Kameda T; Konoshi T; Miyagawa T; Takayama T; Morita T
BMC Urol; 2018 May; 18(1):51. PubMed ID: 29843694
[TBL] [Abstract][Full Text] [Related]
19. Trans-rectal ultrasound visibility of prostate lesions identified by magnetic resonance imaging increases accuracy of image-fusion targeted biopsies.
Ukimura O; Marien A; Palmer S; Villers A; Aron M; de Castro Abreu AL; Leslie S; Shoji S; Matsugasumi T; Gross M; Dasgupta P; Gill IS
World J Urol; 2015 Nov; 33(11):1669-76. PubMed ID: 25656687
[TBL] [Abstract][Full Text] [Related]
20. Transrectal ultrasound examination of prostate cancer guided by fusion imaging of multiparametric MRI and TRUS: avoiding unnecessary mpMRI-guided targeted biopsy.
Xu G; Li JH; Xiang LH; Yang B; Chen YC; Sun YK; Zhao BH; Wu J; Sun LP; Xu HX
Asian J Androl; 2023; 25(3):410-415. PubMed ID: 36348578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
